Q2 FY2026 · ended Jun 30, 2026 · Revenue $227,629 · Filed Aug 12, 2026
Decoy Therapeutics Inc. (DCOY) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $227,629 and a net loss of $2.4 million.
Revenue
$227,629
Net income
$-2.37M
-147.8% vs year-ago quarter
Operating cash flow
$-2.65M
-207.6% vs year-ago quarter
Free cash flow
—
EPS
$-4.46
+94.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
655,185
-91.4% vs year-ago quarter
Net cash
—
Operating margin
-1155.8%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DCOY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1615219
- Former names
- Salarius Pharmaceuticals, Inc. (until Jan 9, 2026); Flex Pharma, Inc. (until Jul 22, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $227,629 | — | — | — | — |
| Operating income | -$2.6M | -$2.3M | -$9.0M | -$895,130 | -$965,565 |
| Net income | -$2.4M | -$2.2M | -$9.0M | -$873,467 | -$957,825 |
| Diluted EPS | -$4.46 | -$4.18 | $25.96 | -$1.81 | -$81.21 |
| Operating cash flow | -$2.7M | -$2.9M | -$1.1M | -$1.6M | -$862,297 |
| Total assets | $9.0M | $8.4M | $11.1M | $6.1M | $1.4M |
| Total liabilities | $4.7M | $4.5M | $5.2M | $1.8M | $2.2M |
| Stockholders' equity | $4.3M | $3.9M | $5.9M | $4.2M | -$829,724 |
| Cash and investments | $8.3M | $7.8M | $10.7M | $4.8M | $794,886 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 23, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 15, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 15, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jun 29, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Other events
|
May 19, 2026 | May 19, 2026 |
All 743 Decoy Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.